

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 09/10/24
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 09/10/24
<b>Clinical Policy Document:</b> Radiation Therapy, Neutron Beam	<b>Replaces Effective Clinical Policy Dated:</b> 09/28/23
<b>Reference #:</b> MC/L024	<b>Page:</b> 1 of 3

**PURPOSE:**

The intent of this clinical policy is to ensure services are medically necessary

Please refer to the member's benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member's benefit plan or certificate of coverage, the terms of the member's benefit plan document will govern.

**POLICY:**

Benefits must be available for health care services. Health care services must be ordered by a provider. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration.

**GUIDELINES:**

Medical Necessity Criteria – Request for neutron beam therapy for the treatment of salivary gland tumors  
– Must satisfy any of the following: I - III

- I. Inoperable tumor; or
- II. Locally advanced tumor especially in persons with gross residual disease; or
- III. Unresectable tumor.

**EXCLUSIONS (not limited to):**

Refer to member's Certificate of Coverage or Summary Plan Description

Neutron beam therapy is investigative for all other indications including, such as but not limited to (see Investigative List): I - XI

- I. Colon cancer
- II. Dermatofibrosarcoma protuberans
- III. Ghost cell odontogenic carcinoma
- IV. Glioma
- V. Kidney cancer
- VI. Laryngeal cancer
- VII. Lung cancer
- VIII. Pancreatic cancer
- IX. Prostate cancer
- X. Rectal cancer
- XI. Soft tissue sarcoma

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 09/10/24
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 09/10/24
<b>Clinical Policy Document:</b> Radiation Therapy, Neutron Beam	<b>Replaces Effective Clinical Policy Dated:</b> 09/28/23
<b>Reference #:</b> MC/L024	<b>Page:</b> 2 of 3

## BACKGROUND:

Most radiation therapies utilize photons -- lightweight particles that damage cancerous cells. Neutron beam radiation therapy (NBRT) uses neutrons, which are much heavier than photons and appear to be more effective in destroying very dense tumors. Compared to roentgen ray (X-ray), neutrons are characterized by several properties:

- reduced oxygen enhancement factor,
- less or no repair of sub-lethal or potentially lethal cell damage, and
- less variation of sensitivity through cell cycle.

NBRT is a specialized type of EBRT that uses high energy neutrons (neutral charged subatomic particles). The neutrons are targeted toward tissue masses that are characterized by lower tumor oxygen levels and a slower cell cycle, since neutrons require less oxygen and are less dependent on the cell's position in the cell division cycle. Neutrons impact with approximately 20 to 100 times more energy than conventional photon radiation and may be more damaging to surrounding tissues. For that reason, the radiation is delivered utilizing a sophisticated planning and delivery system.

Neutron beam therapy entails the use of a particle accelerator; protons from the accelerator are deflected by a magnet to a target which creates the neutron beam. Neutron beam therapy has been employed mainly for the treatment of the salivary gland cancers. It has also been used to treat other malignancies such as soft tissue sarcoma (STS) as well as lung, pancreatic, colon, kidney and prostate cancers. Nevertheless, NBRT has not gained wide acceptance because of the clinical difficulty in generating neutron particles. It should be noted that NBRT is different from boron neutron capture therapy (BNCT), which is a radiotherapy based on the preferential targeting of tumor cells with non-radioactive isotope ( $^{10}\text{B}$ ) and subsequent activation with thermal neutrons to produce a highly localized radiation, and is often used to treat brain tumors. In BNCT, the patient is given a drink containing boron, which is taken up by tumor cells. The tumor is then irradiated with a neutron beam, causing the boron to split into two highly energetic particles (helium and lithium) that destroy the cancerous cells while largely sparing adjacent healthy cells.

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 09/10/24
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 09/10/24
<b>Clinical Policy Document:</b> Radiation Therapy, Neutron Beam	<b>Replaces Effective Clinical Policy Dated:</b> 09/28/23
<b>Reference #:</b> MC/L024	<b>Page:</b> 3 of 3

Prior Authorization: Yes, per network provider agreement

#### **CODING:**

CPT® or HCPCS

77423 High energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)

CPT codes copyright 2024 American Medical Association. All Rights Reserved. CPT is a trademark of the AMA. The AMA assumes no liability for the data contained herein.

#### **REFERENCES:**

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: Coverage Determination Guidelines (MP/C009)
3. American Cancer Society (ACS). Radiation Therapy for Salivary Gland Cancer. Last Revised: March 18, 2022. Retrieved from: <https://www.cancer.org/cancer/salivary-gland-cancer/treating/radiation-therapy.html> Accessed 06-17-24.
4. American Cancer Society (ACS). Salivary Gland Cancer. Retrieved from <https://www.cancer.org/cancer/types/salivary-gland-cancer.html>. Accessed 06-17-24.
5. Davis C, Sikes J, Namaranian P, Laramore G, Dillon JK. Neutron Beam Radiation Therapy: An Overview of Treatment and Oral Complications When Treating Salivary Gland Malignancies. *J Oral Maxillofac Surg*. 2016 Apr;74(4):830-5.
6. Lydiatt WM, Quivey JM. Salivary gland tumors: Treatment of locoregional disease. (Topic 3377, Version 38.0; last updated 12/20/23). In: Shah S, ed. *UpToDate*. Waltham, Mass. UpToDate; 2023. [www.uptodate.com](http://www.uptodate.com). Accessed 06-17-24.
7. American Society of Clinical Oncology (ASCO). Management of salivary gland malignancy: ASCO guideline. *Journal of Clinical Oncology*. 2021;39(17). Retrieved from <https://ascopubs.org/doi/10.1200/JCO.21.00449>. Accessed 06-17-24.
8. National Comprehensive Cancer Network (NCCN) Guidelines. Head and Neck Cancers. Version 4.2024, 05-01-24. Retrieved from [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf). Accessed 06-17-24.

#### **DOCUMENT HISTORY:**

<b>Created Date:</b> 11/05/20
<b>Reviewed Date:</b> 07/06/21, 06/08/22, 06/08/23, 06/07/24
<b>Revised Date:</b>

# Nondiscrimination & Language Access Policy



Discrimination is Against the Law. Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex, (including sex characteristics, including intersex traits; pregnancy or related conditions; sexual orientation, gender identity and sex stereotypes), consistent with the scope of sex discrimination described at 45 CFR § 92.101(a)(2). Aspirus Health Plan, Inc. does not exclude people or treat them less favorably because of race, color, national origin, age, disability, or sex.

Aspirus Health Plan, Inc.:

Provides people with disabilities reasonable modifications and free appropriate auxiliary aids and services to communicate effectively with us, such as:

- Qualified sign language interpreters.
- Written information in other formats (large print, audio, accessible electronic formats, other formats).

Provides free language assistance services to people whose primary language is not English, which may include:

- Qualified interpreters.
- Information written in other languages.

If you need reasonable modifications, appropriate auxiliary aids and services, or language assistance services, contact the Nondiscrimination Grievance Coordinator at the address, phone number, fax number, or email address below.

If you believe that Aspirus Health Plan, Inc. has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a *grievance* with:

Nondiscrimination Grievance Coordinator  
Aspirus Health Plan, Inc.  
PO Box 1890  
Southampton, PA 18966-9998  
Phone: 1-866-631-5404 (TTY: 711)  
Fax: 763-847-4010  
Email: customerservice@aspirushealthplan.com

You can file a *grievance* in person or by mail, fax, or email. If you need help filing a *grievance*, the Nondiscrimination Grievance Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services  
200 Independence Avenue, SW  
Room 509F, HHH Building  
Washington, D.C. 20201  
1.800.368.1019, 800.537.7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>. This notice is available at Aspirus Health Plan, Inc.'s website: [https://aspirushealthplan.com/webdocs/70021-AHP-NonDiscrim\\_Lang-Assist-Notice.pdf](https://aspirushealthplan.com/webdocs/70021-AHP-NonDiscrim_Lang-Assist-Notice.pdf).

## Language Assistance Services

**Albanian:** KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë. Telefononi në 1-800-332-6501 (TTY: 711).

**Arabic:** تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية متاحة لك مجاناً. اتصل بن أعلى رقم الهاتف 1-800-332-6501 (رقم هاتف الصم والبك : 711)

**French:** ATTENTION: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-800-332-6501 (ATS: 711).

**German:** ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-800-332-6501 (TTY: 711).

**Hindi:** यान द : य द आप िहंदी बोलते ह तो आपके िलए मु त म भाषा सहायता सेवाएं उपल थ ह 1-800-332-6501 (TTY: 711) पर कॉल कर ।

**Hmong:** LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1-800-332-6501 (TTY: 711).

**Korean:** 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-800-332-6501 (TTY: 711) 번으로 전화해 주십시오.

**Polish:** UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1-800-332-6501 (TTY: 711).

**Russian:** ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-800-332-6501 (телетайп: 711).

**Spanish:** ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-332-6501 (TTY: 711).

**Tagalog:** PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1-800-332-6501 (TTY: 711).

**Traditional Chinese:** 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-800-332-6501 (TTY: 711)

**Vietnamese:** CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-800-332-6501 (TTY: 711).

**Pennsylvania Dutch:** Wann du Deutsch (Pennsylvania German / Dutch) schwetzscht, kannst du mitaue Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1-800-332-6501 (TTY: 711).

**Lao:** ໂປດຊາບ: ຖ້າວ່າທ່ານເວົ້າພາສາລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາໂດຍບໍ່ເສັຽຄ່າ, ຄວນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1-800-332-6501 (TTY: 711).